Group 1 - The company will hold its second extraordinary general meeting of shareholders on November 25, 2025, to discuss additional proposals [1][3] - Zhejiang International Trade Group Co., Ltd., the controlling shareholder, proposed to add a temporary proposal regarding the loan limit to the company's subsidiary [2][19] - The proposal has been approved by the independent directors and the board of directors, and it complies with relevant laws and regulations [2][19] Group 2 - The loan amount proposed is 1.3 billion yuan, intended for daily operations and debt replacement, with a validity period until July 20, 2026 [13][19] - The loan interest rate will not exceed 3.15% and will be subject to the weighted average interest rate of bank loans at the time of borrowing [13][19] - The board meeting on November 13, 2025, approved the proposal with a unanimous vote, excluding the related director from voting [42][43] Group 3 - The company is also establishing the "Oriental Zheyao Zhongying Binjiang Medical Fund" with a target size of 500 million yuan, involving several partners [21][22] - The fund will focus on supporting the biopharmaceutical and medical device industries, with a management fee of 0.75% per year during the investment period [31][38] - The fund's investment strategy includes a cap on single investments and a focus on mid to late-stage projects [33][38]
浙江东方金融控股集团股份有限公司关于2025年第二次临时股东会增加临时提案的公告